Support Biomedical Research in the Economic Stimulus Package

February 11, 2009 | by

This week, Congress is working to reconcile biomedical research funding differences in the American Recovery and Reinvestment Act. According to ProPublica, the Senate bill would spend substantially more on biomedical research than the House bill (10 billion vs. 900 million USD).

It is imperative that you urge your congressional members to support biomedical research as a critical driver of our economy. Here’s why: the biotechnology industry is a major driver of the U.S. economy and has been for the past 30 years [1]. Federal granting agencies have “shovel-ready” projects that will promote economic growth today — those research projects will help fight disease and improve the quality of life for everyone in America tomorrow.

Viral-based Human Disease and the Nobel Prize for Medicine

October 10, 2008 | by

nobel medal in medicineThe 2008 Nobel Prize in Physiology or Medicine was announced earlier this week. The prize was awarded to three europeans for the discoveries of two viruses that cause severe human disease; the cancer-causing human papilloma virus (HPV) and the human immunodeficiency virus (HIV).

Two French scientists, Luc Montagnier, age 76, at the University of Paris in Paris, France and Francoise Barré-Sinoussi, age 61, at the Institut Pasteur in Garches, France will split half the prize for their discovery of the HIV virus. Barré-Sinoussi is the 8th woman to receive the Nobel award for Physiology or Medicine.

A German researcher, Harald zur Hausen, age 72, at the University of Dusseldorf, Germany, will receive the other half of the $1.3 million prize for establishing that most cervical cancers are caused by two types of human papilloma virus.

NIH Increases Support for High-risk Large-impact Biomedical Research

October 2, 2008 | by

The National Institutes of Health (NIH) announced last week that it has increased support for high-risk, large-impact research by awarding 16 investigators the Pioneer Award; 2.5 million for each investigator over five years to pursue research in a variety of areas, including embroyonic development, autism, prions (responsible for the formation of amyloid plaques that lead to neurodegeneration) and malaria [1].

The NIH Director’s Pioneer Award is a high-risk research initiative desiged to [2]:

… support individual scientists of exceptional creativity who propose pioneering — and possibly transforming approaches — to major challenges in biomedical and behavioral research.

First announced in 2004, 9 awards were presented in September 2004, 13 awards each were made in 2005 and 2006, and 12 awards were presented last year.

The Kanzius Machine: A Future Alternative to Chemotherapy?

April 17, 2008 | by

Last Sunday, 60 Minutes profiled John Kanzius, an inventor who may have come up with one of the most promising breakthroughs in cancer research in years. It’s still in the experimental stage and much research needs to be done, but if future clinical trials are successful, the Kanzius Machine will destroy cancer cells throughout the body without need for drugs or surgery.

Funding of Childhood Cancer, NF Research in Jeopardy

March 31, 2008 | by

Neurofibromatosis (NF) is a set of genetic disorders that can cause tumors to develop and grow along various types of nerves. The tumors may also affect the development of non-nervous system tissues such as skin and bone.

There are three types of NF tumors that result from mutation or loss of different tumor suppressor genes:

  • Neurofibromatosis type 1 (NF1) is the most frequent inherited cause of brain and nerve tumors. One in every 3,000 children is born with NF1, making it also one of the most common inherited human diseases worldwide. Enlargement and deformation of bones may also occur. Approximately 50% of people with NF1 also have learning disabilities. NF1 is caused by a mutation or loss of the tumor suppressor gene NF1.
  • Neurofibromatosis type 2 (NF2) is much rarer, occurring in one in 25,000 births. NF2 is characterized by the development of multiple tumors on the cranial and spinal nerves. The hallmark of NF2 is the formation of tumors that affect auditory nerves. Hearing loss beginning in the teens or early twenties is typically the first symptom of NF2. NF2 is caused by a mutation or loss of the tumor suppressor gene NF2.
  • Schwannomatosis is even rarer than NF2, affecting one in 40,000 individuals. SImilar to NF1 and NF2, Schwannomatosis tumors can develop on cranial, spinal and/or peripheral nerves. Although patients with Schwannomatosis do not have learning disabilities, they experience chronic pain and occasionally numbness, tingling and weakness. The candidate Schwannomatosis tumor suppressor gene is named INI1.